<DOC>
	<DOCNO>NCT00550030</DOCNO>
	<brief_summary>Etanercept , biological antipsoriatic drug anti-tumor-necrosis factor ( TNF ) activity approve treatment moderate severe psoriasis . However , substantial portion case etanercept induce reduction psoriasis area severity index ( PASI ) 75 % great , consider gold standard treatment efficacy . In study researcher aim determine randomize half-side comparison , whether additional narrowband UVB-311nm phototherapy accelerate improve therapeutic efficacy etanercept .</brief_summary>
	<brief_title>Etanercept Plus UVB-311nm Phototherapy Psoriasis</brief_title>
	<detailed_description>Patients moderate severe psoriasis receive standard dose etanercept ( 50 mg 25 mg s.c. twice weekly ) least 6 week without PASI reduction 75 % great qualify study . Etanercept continue UVB-311nm phototherapy add 6 week thereafter randomize body half ( left right ; head exempt ) 3 x per week complete response ( define reduction PASI &lt; 3 ) maximum another 6 week ( week 12 ) . PASI score patient disease score assessed weekly ; patient life quality score week 0 , 6 , 12 ; score follow-up visit month 3 , 6 , 12 . Paired statistical testing ( T-test Wilcoxon ) differences PASI patient disease life quality score do ; Fischer exact test apply determine difference complete remission , PASI reduction &gt; 90 % , &gt; 75 % , and/or 50 % body sit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients moderate severe psoriasis receive standard dose etanercept ( 50 mg 25 mg s.c. twice weekly ) least 6 week without PASI reduction 75 % great Pregnancy lactation Presence history malignant skin tumor Dysplastic melanocytic nevus syndrome Antinuclear antibody ( dsDNA , Ro/SSA , La/SSB ) Autoimmune disorder Lupus erythematosus Dermatomyositis Photosensitive diseases porphyria , chronic actinic dermatitis , Xeroderma pigmentosum , basal cell nevus syndrome , others General poor health status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>UVB radiation</keyword>
	<keyword>Biologics</keyword>
	<keyword>Etanercept</keyword>
	<keyword>PASI</keyword>
</DOC>